表紙
市場調査レポート

内臓痛覚:パイプライン製品の分析

Visceral Pain - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 283207
出版日 ページ情報 英文 64 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
内臓痛覚:パイプライン製品の分析 Visceral Pain - Pipeline Review, H1 2016
出版日: 2016年03月30日 ページ情報: 英文 64 Pages
概要

内臓痛覚とは、内臓から発生する侵害受容性疼痛の一種です。主な症状には、うずくような痛み(疼痛)や締め付けられるような痛み、拡散するような痛みなどが挙げられます。主な治療薬には、鎮痛剤(麻酔・NSAID(非ステロイド系抗炎症性薬物)ほか)や修飾薬(三環系抗うつ剤・抗けいれん薬ほか)などがあります。

当レポートでは、世界各国での内臓痛覚治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

内臓痛覚の概要

治療薬の開発

  • 内臓痛覚向けパイプライン製品:概要
  • 内臓痛覚向けパイプライン製品:比較分析

各企業で開発中の内臓痛覚治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

内臓痛覚治療薬:開発中の製品の一覧(企業別)

内臓痛覚治療薬の開発に従事している企業

  • Addex Therapeutics Ltd
  • Amorepacific Corporation
  • Aros Pharma ApS
  • アステラス製薬
  • Echo Pharmaceuticals B.V.
  • GIcare Pharma Inc
  • Grunenthal GmbH
  • Hydra Biosciences, Inc.
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Neurim Pharmaceuticals Ltd
  • ObsEva SA
  • PDC Biotech GmbH
  • Proteus SA
  • RDD Pharma Ltd.
  • Thar Pharmaceuticals, Inc.
  • Trevena, Inc.

内臓痛覚:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • ADX-71441
  • ASP-7663
  • dronabinol
  • GIC-1001
  • GIC-1002
  • HC-030031
  • MK-8342B
  • 急性疼痛および慢性膵炎の疼痛のためのTGF-Beta-1を阻害する抗体
  • neosaxitoxin
  • NeuP-12
  • nifedipine
  • NKTR-195
  • OBE-002
  • PAC-14028
  • PDC-41、など

内臓痛覚治療薬:パイプライン製品の最新動向

内臓痛覚治療薬:休止中のプロジェクト

内臓痛覚治療薬:開発が中止された製品

内臓痛覚治療薬:製品開発のマイルストーン

主なニュースと発表

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7727IDB

Summary

Global Markets Direct's, 'Visceral Pain - Pipeline Review, H1 2016', provides an overview of the Visceral Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Visceral Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Visceral Pain
  • The report reviews pipeline therapeutics for Visceral Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Visceral Pain therapeutics and enlists all their major and minor projects
  • The report assesses Visceral Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Visceral Pain

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Visceral Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Visceral Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Visceral Pain Overview
  • Therapeutics Development
    • Pipeline Products for Visceral Pain - Overview
    • Pipeline Products for Visceral Pain - Comparative Analysis
  • Visceral Pain - Therapeutics under Development by Companies
  • Visceral Pain - Therapeutics under Investigation by Universities/Institutes
  • Visceral Pain - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Visceral Pain - Products under Development by Companies
  • Visceral Pain - Products under Investigation by Universities/Institutes
  • Visceral Pain - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Amorepacific Corporation
    • Aros Pharma ApS
    • Astellas Pharma Inc.
    • Echo Pharmaceuticals B.V.
    • GIcare Pharma Inc
    • Grunenthal GmbH
    • Nektar Therapeutics
    • Neurim Pharmaceuticals Ltd
  • Visceral Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADX-71743 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-7663 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dronabinol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GIC-1002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NEO-5024 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NEO-5937 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NeuP-12 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKTR-195 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PAC-14028 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • piromelatine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PPC-5650 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PR-38 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RO-656570 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Activate OXTR for Oncology and Abdominal Pain - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • URB-937 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Visceral Pain - Recent Pipeline Updates
  • Visceral Pain - Dormant Projects
  • Visceral Pain - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Visceral Pain, H1 2016
  • Number of Products under Development for Visceral Pain - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Visceral Pain - Pipeline by Addex Therapeutics Ltd, H1 2016
  • Visceral Pain - Pipeline by Amorepacific Corporation, H1 2016
  • Visceral Pain - Pipeline by Aros Pharma ApS, H1 2016
  • Visceral Pain - Pipeline by Astellas Pharma Inc., H1 2016
  • Visceral Pain - Pipeline by Echo Pharmaceuticals B.V., H1 2016
  • Visceral Pain - Pipeline by GIcare Pharma Inc, H1 2016
  • Visceral Pain - Pipeline by Grunenthal GmbH, H1 2016
  • Visceral Pain - Pipeline by Nektar Therapeutics, H1 2016
  • Visceral Pain - Pipeline by Neurim Pharmaceuticals Ltd, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Visceral Pain Therapeutics - Recent Pipeline Updates, H1 2016
  • Visceral Pain - Dormant Projects, H1 2016
  • Visceral Pain - Dormant Projects (Contd..1), H1 2016
  • Visceral Pain - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Visceral Pain, H1 2016
  • Number of Products under Development for Visceral Pain - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top